This release about the first set of tests in patients prescribed an experimental cancer drug, abemaciclib, uses language that mostly hews to the careful tone of the researchers’ journal article. It does not make any premature claims of cure or even extended survival. The release includes sections labeled “Limitations” and “Funding & Disclosures” that highlight these vital elements. We would have liked to see at least some discussion of the possible cost of the drug, especially since a similar drug mentioned in the release is priced around $10,000/month. The release could have explicitly noted that the new drug could fail ongoing trials, instead of using language that implies eventual success. Even with expedited status and favorable study results, it would likely be 1-3 years before this drug could be approved for routine use.
People with cancer are on the lookout for any potential new treatment. Writers of news releases about experimental cancer drugs must be careful not to imply benefits that have not been proven. As this release demonstrates, even when there are no claims of cure or even extended survival, readers can come away with an inflated sense of the likely success of a drug that is only beginning to be tested in people. This study highlights a second agent in a new class of medicines that may broadly target a range of cancer types that may have similar mechanisms of action. Which cancers, at what stage and for which patients still needs to be determined. Moreover, it will need to be compared to other established and experimental medicines to determine its relative benefits and harms.
While one could say it is far too soon to start talking about the cost of a drug that is only beginning to be tested in people, the release compared abemaciclib to a somewhat similar drug, palbociclib (brand name: Ibrance) that is listed at approximately $10,000/month. The release could have referred to the costs of similar drugs… and perhaps included some mention of how long researchers anticipate patients would be treated with this sort of drug. As an aside, the Wall Street Journal reported a fascinating story on how Pfizer set the (just under) $10,000/month list price of Ibrance.
The release is appropriately restrained in its description of the potential benefits of a drug just starting the long process of trials in patients. It specifically reports the number of trial participants whose tumors appeared to respond or at least not advance during the test, without making premature claims of effectiveness. However, we would like to see news releases about early trials of cancer drugs go further, to state explicitly that signs of partial responses or stable disease do not imply potential cures or even extended survival. More emphatic cautionary statements seem particularly appropriate to releases like this one that point out an experimental drug has been given “breakthrough therapy designation” by the FDA, which is a technical definition that the FDA notes is frequently misinterpreted by the public and even health care professionals. Since it referenced “durable response,” it would have been nice to see the release include a definition. In brief, the term refers to the length of time that a partial or complete response is observed as a result of treatment.
The release notes that “the most common treatment-related adverse events were fatigue, diarrhea, nausea, vomiting, anorexia, weight loss, kidney dysfunction, and decreased red and white blood cell counts.” Although the release does not go into specific detail about the number of patients who reported side effects, or the degree of severity of the side effects, the list of harms seems adequate for a drug just beginning the clinical trial process.
The release clearly summarizes what the researchers reported in their article in the Cancer Discovery medical journal; that is, that this test involving just a couple of hundred patients showed the drug could be tolerated at doses that seem to show some effects on some tumors. We applaud the news release for including a paragraph labeled “Limitations” that stated only 225 patients with different forms of cancer were involved, so further tests are needed to determine what role this drug might have in cancer care. The release would have been stronger if it had spelled out that the study was performed in patients who had failed prior treatments so readers won’t assume this drug could be used for first line therapy.
The release does not exaggerate the seriousness of the cancers that were studied.
The release includes a “Funding & Disclosures” paragraph. It lists funding by Eli Lilly and Company. It also lists some of the payments and other connections between key researchers and the company. We like the format used for this EurekAlert version of the release, which also notes the funder in a box just to the right of the release’s headline.
The release spells out some specific features of abemaciclib that explain why researchers think it has potential advantages over a similar drug that is already FDA-approved. However, this comparison puts the new drug in an entirely positive light, which it has yet to demonstrate it deserves. We’ll dock points for that concern here. Since the comparison with the competing drug also speaks to abemaciclib’s novelty, we’ll award a Satisfactory for that criterion (see below) so as not to double-ding the release.
The release notes that abemaciclib is now being tested in trials designed to “define the role of abemaciclib in cancer care.” However, it never explicitly states that these trials might end up finding that the drug does not ultimately provide sufficient advantages over existing treatments. Its reference to “investigational” in the title and text may be enough to give some readers the tip-off that this drug won’t be available anytime soon. However, we recommend news release writers make it abundantly clear when a drug is only available as part of research trials and that it is not available for use in routine clinical practice. The statement, “FDA decision to grant breakthrough therapy designation,” may lead a reader to think this could be available for use more broadly.
The release explains that although there are other drugs that attack cancer cells in a similar way, this drug has some differences. As noted above, the release casts all the differences with existing drugs as advantages, when of course these features have yet to be adequately tested.
The release avoids unjustified claims, although the overall cast is entirely positive, leaving it to journalists and other readers to balance the rosy image with some skepticism.
Systematic, Criteria-Driven
Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's @CarlaKJohnson. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like